



(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 25/16 (2006.01)
A61K 51/00 (2006.01) A61P 25/28 (2006.01)
A61P 25/00 (2006.01) C07K 16/18 (2006.01)
A61P 25/02 (2006.01)

(21) International Application Number:

PCT/EP2022/075402

(22) International Filing Date:

13 September 2022 (13.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

EP21197120 16 September 2021 (16.09.2021) EP

(71) Applicant: **H. LUNDBECK A/S** [DK/DK]; Ottilievej 9,
2500 Valby (DK).


(72) Inventors: **NIELSEN SØDERBERG, Josefine**; c/o
H. Lundbeck A/S, Ottilievej 9, 2500 Valby (DK).
KALLUNKI, Pekka; c/o H. Lundbeck A/S, Ottilievej 9,

2500 Valby (DK). **BUUR, Louise**; c/o H. Lundbeck A/S,
Ottilievej 9, 2500 Valby (DK). **LARSEN, Frank**; c/o H.
Lundbeck A/S, Ottilievej 9, 2500 Valby (DK). **PARSHAD,**
Henrik Rajesh Kumar; c/o H. Lundbeck A/S, Ottilievej
9, 2500 Valby (DK). **MARKUSSEN, Anne Sofie**; c/o H.
Lundbeck A/S, Ottilievej 9, 2500 Valby (DK). **MANNING,**
Mark Cornell; 4630 Sorrel Lane, Johnstown, Colorado
80534 (US). **KATAYAMA, Derrick Spencer**; 6773 Flint-
lock Rd, Timnath, Colorado 80547 (US). **GAUDEN, Mag-**
dalena; c/o Lonza Biologics plc, 228 Bath Road, Slough,
Berkshire SL1 4DX (GB). **SMITH, John**; c/o Lonza Bi-
ologics plc, 228 Bath Road, Slough, Berkshire SL1 4DX
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,

(54) Title: COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES

Figure 1



(57) Abstract: The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

11 May 2023 (11.05.2023)